Supriya Lifescience Limited (NSE:SUPRIYA)

India · Delayed Price · Currency is INR

925.00

-25.25 (-2.66%)

Oct 1, 2026, 3:29 PM IST

Market Cap	74.93B +27.7%
Revenue (ttm)	8.73B +28.1%
Net Income	1.98B +11.4%
EPS	24.65 +11.4%
Shares Out	80.48M
PE Ratio	37.76
Forward PE	n/a
Dividend	1.00 (0.11%)
Ex-Dividend Date	Sep 4, 2026

Volume	209,081
Open	942.45
Previous Close	950.25
Day's Range	913.30 - 948.25
52-Week Range	545.50 - 1,085.00
Beta	0.65
Analysts	Buy
Price Target	940.00 (+1.62%)
Est. Earnings	Nov 13, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1987

Employees 607

Stock Exchange National Stock Exchange of India

Ticker Symbol SUPRIYA

Full Company Profile

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SUPRIYA stock is "Buy." The 12-month stock price target is ₹940.00, which is an increase of 1.62% from the latest price.

Price Target

₹940.00

(1.62% upside)

Analyst Consensus: Buy

Stock Forecasts